Hotline 24/7: 0909384389

Share links:

MeRes100 BRS demonstrates sustained safety and efficacy

Ngày 06/07/2019 09:36 | Lượt xem: 1512

Data from the MeRes-1 and MeRes-1 Extend clinical trials, released at EuroPCR 2019 (20–24 May, Paris, France), demonstrate sustained efficacy and safety for the recently CE-approved MeRes100 (Meril) bioresorbable scaffold (BRS).

A press release from Meril describes it as a next generation, thin strut sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo coronary artery lesions. Both trials demonstrated zero scaffold thrombosis and a very low major adverse cardiac event (MACE) rate of 1.87% at three years as shown in MeRes-1, and 1.61% in MeRes-1 Extend at two years.

Ashok Seth (New Dehli, India), principal investigator for the MeRes-1 trial presented the data at EuroPCR. In the press release, he states: “First generation bioresorbable scaffolds have not shown the most favourable results at long term. MeRes100, a next-generation bioresorbable scaffold, has been developed with reduced strut thickness, an improved profile for better deliverability, faster degradation and possibly lower scaffold thrombosis.”

A press release from Meril describes it as a next generation, thin strut sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo coronary artery lesions. Both trials demonstrated zero scaffold thrombosis and a very low major adverse cardiac event (MACE) rate of 1.87% at three years as shown in MeRes-1, and 1.61% in MeRes-1 Extend at two years.

Ashok Seth (New Dehli, India), principal investigator for the MeRes-1 trial presented the data at EuroPCR. In the press release, he states: “First generation bioresorbable scaffolds have not shown the most favourable results at long term. MeRes100, a next-generation bioresorbable scaffold, has been developed with reduced strut thickness, an improved profile for better deliverability, faster degradation and possibly lower scaffold thrombosis.”

Source CardiovascularNews

Duc Tin Clinic

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support